JOURNAL OF BIOLOGICAL REGULATORS & HOMEOSTATIC AGENTS Vol. 33, no. 4, 1019-1022 (2019)


Mesenchymal stem cells and IL-37: a powerful combination.

Gugliandolo A1, Caraffa AL2, Gallenga CE3, Kritas SK4, Ronconi G5, Trubiani O6, Pio Conti 7, Di Emidio P8, Mazzon E1.

Author information

1 IRCCS Centro Neurolesi “Bonino Pulejo”, Messina, Italy.
2 School of Pharmacy, University of Camerino, Camerino, Italy.
3 Department of Biomedical Sciences and Specialist Surgery, Section of Ophthalmology, University of Ferrara, Ferrara, Italy.
4 Department of Microbiology and Infectious Diseases, School of Veterinary Medicine, Aristotle University of Thessaloniki, Macedonia, Greece.
5 Clinica dei Pazienti del Territorio, Fondazione Policlinico Gemelli, Rome, Italy.
6 Department of Oral and Biotechnology Medical Science, University of Chieti-Pescara, Chieti, Italy.
7 Postgraduate Medical School, University of Chieti, Chieti, Italy.
8 Maxillofacial Surgery “G. Mazzini” Hospital, Teramo, Italy.

Abstract

Mesenchymal stem cells (MSCs) are able to exert immunomodulatory and anti-inflammatory actions. Thanks to these properties, MSCs may be a promising alternative approach for the treatment of inflammatory disease. Important cytokines involved in inflammation are those included in the IL-1 family. Interleukin-37 (IL-37) is one of the member able to suppress both innate and adaptive immunity. Recently, it was found that MSCs and their derivatives can modulate IL-37, and MSCs expressing IL-37 seem to have an enhanced therapeutic efficacy.

KEYWORDS:

IL-37, inflammation, mesenchymal stem cells

Publication type

  • Editorial

You may also like...